

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CHINA MEDICAL SYSTEM HOLDINGS LIMITED**  
**康哲藥業控股有限公司** \*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 867)**

**Voluntary and Business Update Announcement**  
**Collaboration Agreement with University of Cambridge, acting through its Cambridge Judge Business School, and AstraZeneca**

China Medical System Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group, through its wholly-owned subsidiary of the Company, has signed a Collaboration Agreement (the “**Collaboration Agreement**” ) dated 5 December 2019 with the University of Cambridge, acting through its Cambridge Judge Business School (“**CJBS**”), and AstraZeneca UK Limited (“**AstraZeneca**”). Through the collaboration, the Company will invest in the UK biotech and life sciences sectors over the next five years, with support from the established networks and relationships of AstraZeneca and CJBS.

The Company’s investment may provide it with the opportunity to secure rights to the products developed by the invested companies in the future for Greater China (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan).

Since 2015, AstraZeneca has played a role in mentoring biotech and life sciences researchers and innovators and has partnered with CJBS on various programmes to promote enterprise and support entrepreneurship amongst life sciences researchers and students.

Through the Collaboration Agreement, the Company, AstraZeneca and CJBS demonstrate a common objective of strengthening the pipeline of opportunities in biotech and life sciences, more specifically in the areas of therapeutics, diagnostics, devices and digital health, thus providing the invested companies with greater access to international markets in particular Greater China.

By order of the Board  
China Medical System Holdings Limited  
**Lam Kong**  
*Chairman*

Hong Kong, 5 December 2019

*As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong, Mr. Chen Hongbing and Ms. Chen Yanling as executive directors; and (ii) Mr. Cheung Kam Shing, Terry, Mr. Wu Chi Keung and Mr. Leung Chong Shun as independent non-executive directors.*